These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1029 related items for PubMed ID: 11408506

  • 1. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
    Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS.
    J Clin Oncol; 2001 Jun 15; 19(12):3091-102. PubMed ID: 11408506
    [Abstract] [Full Text] [Related]

  • 2. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, Breneman JC, Wiener ES, Crist WM.
    J Clin Oncol; 2000 Jun 15; 18(12):2427-34. PubMed ID: 10856103
    [Abstract] [Full Text] [Related]

  • 3. The Third Intergroup Rhabdomyosarcoma Study.
    Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R.
    J Clin Oncol; 1995 Mar 15; 13(3):610-30. PubMed ID: 7884423
    [Abstract] [Full Text] [Related]

  • 4. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group.
    J Clin Oncol; 2006 Aug 20; 24(24):3844-51. PubMed ID: 16921036
    [Abstract] [Full Text] [Related]

  • 5. The Intergroup Rhabdomyosarcoma Study-II.
    Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J.
    Cancer; 1993 Mar 01; 71(5):1904-22. PubMed ID: 8448756
    [Abstract] [Full Text] [Related]

  • 6. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
    Wolden SL, Anderson JR, Crist WM, Breneman JC, Wharam MD, Wiener ES, Qualman SJ, Donaldson SS.
    J Clin Oncol; 1999 Nov 01; 17(11):3468-75. PubMed ID: 10550144
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
    Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM.
    J Clin Oncol; 2003 Jan 01; 21(1):78-84. PubMed ID: 12506174
    [Abstract] [Full Text] [Related]

  • 8. Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.
    Hawkins DS, Anderson JR, Paidas CN, Wharam MD, Qualman SJ, Pappo AS, Scott Baker K, Crist WM.
    J Clin Oncol; 2001 Jun 15; 19(12):3073-9. PubMed ID: 11408504
    [Abstract] [Full Text] [Related]

  • 9. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?
    Arndt CA, Donaldson SS, Anderson JR, Andrassy RJ, Laurie F, Link MP, Raney RB, Maurer HM, Crist WM.
    Cancer; 2001 Jun 15; 91(12):2454-68. PubMed ID: 11413538
    [Abstract] [Full Text] [Related]

  • 10. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR.
    J Clin Oncol; 2011 Apr 01; 29(10):1312-8. PubMed ID: 21357783
    [Abstract] [Full Text] [Related]

  • 11. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS.
    Cancer; 2017 Jun 15; 123(12):2368-2375. PubMed ID: 28211936
    [Abstract] [Full Text] [Related]

  • 12. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
    Smith LM, Anderson JR, Qualman SJ, Crist WM, Paidas CN, Teot LA, Pappo AS, Link MP, Grier HE, Wiener ES, Breneman JC, Raney RB, Maurer HM, Donaldson SS.
    J Clin Oncol; 2001 Oct 15; 19(20):4058-64. PubMed ID: 11600608
    [Abstract] [Full Text] [Related]

  • 13. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?
    Wiener ES, Anderson JR, Ojimba JI, Lobe TE, Paidas C, Andrassy RJ, Raney RB, Qualman SJ, Donaldson SS, Maurer HM, Link MP, Crist WM, Grier HE.
    Semin Pediatr Surg; 2001 Aug 15; 10(3):146-52. PubMed ID: 11481652
    [Abstract] [Full Text] [Related]

  • 14. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS.
    J Clin Oncol; 2014 Nov 01; 32(31):3547-52. PubMed ID: 25267746
    [Abstract] [Full Text] [Related]

  • 15. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
    Donaldson SS, Meza J, Breneman JC, Crist WM, Laurie F, Qualman SJ, Wharam M, Children's Oncology Group Soft Tissue Sarcoma Committee (formely Intergroup Rhabdomyosarcoma Group) representing the Children's Oncology Group and the Quality Assurance Review Center.
    Int J Radiat Oncol Biol Phys; 2001 Nov 01; 51(3):718-28. PubMed ID: 11597814
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB.
    J Pediatr Hematol Oncol; 2001 May 01; 23(4):225-33. PubMed ID: 11846301
    [Abstract] [Full Text] [Related]

  • 17. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP, Anderson JR.
    Pediatr Blood Cancer; 2008 Jan 01; 50(1):33-6. PubMed ID: 17091486
    [Abstract] [Full Text] [Related]

  • 18. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV.
    Michalski JM, Meza J, Breneman JC, Wolden SL, Laurie F, Jodoin M, Raney B, Wharam MD, Donaldson SS.
    Int J Radiat Oncol Biol Phys; 2004 Jul 15; 59(4):1027-38. PubMed ID: 15234036
    [Abstract] [Full Text] [Related]

  • 19. Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
    Abd El-Aal HH, Habib EE, Mishrif MM.
    J Egypt Natl Canc Inst; 2006 Mar 15; 18(1):51-60. PubMed ID: 17237856
    [Abstract] [Full Text] [Related]

  • 20. The Intergroup Rhabdomyosarcoma Study-I. A final report.
    Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, Heyn R, Lawrence W, Newton W, Ortega J.
    Cancer; 1988 Jan 15; 61(2):209-20. PubMed ID: 3275486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.